Diagnosis, screening, prevention, and treatment of osteoporosis.

Osteoporosis is the most common bone disease in humans and affects both men and women. The clinical and public health implications of the disease are substantial because of the mortality, morbidity, and cost of medical care associated with osteoporotic fractures. Osteoporosis is diagnosed on the basis of a low-impact or fragility fracture or low bone mineral density, which was best assessed by central dual-energy x-ray absorptiometry. Both nonpharmacological therapy (calcium and vitamin D supplementation, weight-bearing exercise, and fall prevention) and pharmacological treatments (antiresorptive and anabolic agents) may be helpful in the prevention and treatment of osteoporosis. Therefore, clinicians need to be vigilant in instituting primary prevention measures for those at high risk for osteoporosis and in instituting treatment for patients diagnosed as having the disease either by screening or a history of fracture. This article provides an overview of the diagnosis, screening, prevention, and treatment of osteoporosis.

[1]  R. Recker,et al.  Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .

[2]  P. Tugwell,et al.  Cochrane Review on exercise for preventing and treating osteoporosis in postmenopausal women. , 2004, Europa medicophysica.

[3]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[4]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. , 2002, Endocrine reviews.

[5]  P. Delmas,et al.  Treatment of postmenopausal osteoporosis , 2002, The Lancet.

[6]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[7]  G. Guyatt,et al.  VIII: Meta-Analysis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Women , 2002 .

[8]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[9]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[10]  J. Finkelstein,et al.  The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.

[11]  R. Parker,et al.  Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. , 2003, JAMA.

[12]  G. Spears,et al.  Treatment of postmenopausal osteoporosis with calcitriol or calcium , 1992 .

[13]  D Osterweil,et al.  The value of assessing falls in an elderly population. A randomized clinical trial. , 1990, Annals of internal medicine.

[14]  M. A. Hansen,et al.  Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. , 1992, BMJ.

[15]  Mark Helfand,et al.  Screening for Postmenopausal Osteoporosis: A Review of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[16]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  R. Marcus,et al.  Once‐Weekly Resistance Exercise Improves Muscle Strength and Neuromuscular Performance in Older Adults , 1999, Journal of the American Geriatrics Society.

[18]  J. Reginster,et al.  Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. , 2004, Archives of internal medicine.

[19]  P. Tugwell,et al.  Exercise for preventing and treating osteoporosis in postmenopausal women. , 2011, The Cochrane database of systematic reviews.

[20]  S. Cummings,et al.  Clinical utility of laboratory testing in women with osteoporosis , 2005, Osteoporosis International.

[21]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[22]  Kay Dickersin,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2000, NIH consensus statement.

[23]  M S Calvo,et al.  Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  Gordon Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.

[25]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[26]  E. Orwoll,et al.  Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.

[27]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[28]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  Jeffrey N Katz,et al.  Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. , 2005, Mayo Clinic proceedings.

[30]  Bess Dawson-Hughes,et al.  Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[31]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[32]  B. Ettinger,et al.  Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  R. Heaney.  Optimal calcium intake. , 1995, JAMA.

[34]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[35]  K. Baek,et al.  Official Positions of the International Society for Clinical Densitometry. , 2005 .

[36]  B. Dawson-Hughes,et al.  Calcium supplementation and bone loss: a review of controlled clinical trials. , 1991, The American journal of clinical nutrition.

[37]  E. Schwartz,et al.  Combination Teriparatide and Raloxifene Therapy for Postmenopausal Osteoporosis: Results From a 6‐Month Double‐Blind Placebo‐Controlled Trial , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  J. Kanis,et al.  An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry , 2000, Osteoporosis International.

[39]  P. Lips,et al.  Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55 years of age. , 1991, The Journal of clinical endocrinology and metabolism.

[40]  M. Nevitt,et al.  Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. , 2005, Mayo Clinic proceedings.

[41]  D. Meier,et al.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. , 2002, The Journal of clinical endocrinology and metabolism.

[42]  Bess Dawson-Hughes,et al.  Effect of Vitamin D on falls: a meta-analysis. , 2004, JAMA.

[43]  Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. , 2002, Endocrine reviews.